Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria Nº 1.323, de 25 de novembro de 2013. Ementa: Aprova o Protocolo Clínico e DiretrizesTerapêuticas da Esclerose Múltipla.

Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technology Assessment 2000; 4(9).

Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison: Medicina Interna. 17 ed. Rio de Janeiro: McGraw-Hill, 2008.

Acorda Therapeutics, Inc. Fampridine – SR Advisory Committee Briefing Document, NDA 22-250. Fampridine-SR Tablets For Improvement in Walking Ability in Patients with Multiple Sclerosis. Peripheral & Central Nervous System Drugs Advisory Committee Meeting 2009. [acesso em 19 Dez 2013] Disponível em:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM185664.pdf

U.K. National Institute for Health Research. National Horizon Scanning Centre (NHSC). Fampridine-PR for multiple sclerosis: impaired mobility – first line. University of Birmingham 2010. [acesso em 19 Dez 2013] Disponívelem: http://www.hsc.nihr.ac.uk/topics/fampridine-pr-for-multiple-sclerosis-impaired-mobi/

Miravalle AA. Guidelines and Best Practices for Appropriate use of Dalfampridine in Managed Care Populations. Am J Manag Care 2011;17:154-160. [acesso em 19 Dez 2013] Disponível em: http://www.ajmc.com/publications/supplement/2011/A344_may11/Guidelines-and-Best-Practices-for-Appropriate-Use-of-Dalfampridinein-Managed-Care-Populations/

Anônimo. New Drugs: Fampridine. Australian Prescriber 2011;34(4):119-123. [acesso em 19 Dez 2013]. Disponível em: http://www.australianprescriber.com/magazine/34/4/article/1209.pdf.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Marinucci LN, et al. Susteined-release oral fampridine in multiple sclerosis: a randomized, doubleblind, controlled trial. The Lancet 2009; 373:732-38.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis. Ann Neurol 2010; 68:494-502.

Canada. Canadian Agency for Drugs and Technologies in Health (CADTH). Canadian Drug Expert Committee (CDEC). CDEC Final Recommendation. Fampridine

(Fampyra – Biogen Idec Canada Inc.) Indication: Multiple Sclerosis – Improve Walking Disability. Common Drug Review 2012. [acesso em 19 Dez 2013] Disponível em: http://www.cadth.ca/media/cdr/complete/cdr_complete_Fampyra_Nov-30-12.pdf.